Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials

Abstract Introduction The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treatment efficacy over placebo in patients with PsA, i...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Shawn G. Kwatra, Saakshi Khattri, Ahmad Z. Amin, Roberto Ranza, Blair Kaplan, Linyu Shi, Byron Padilla, Ahmed M. Soliman, Dennis McGonagle
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Adis, Springer Healthcare 2024-05-01
Ráidu:	Dermatology and Therapy
Fáttát:	Biologic Interleukin 23 Psoriasis Psoriatic arthritis Risankizumab Enthesitis
Liŋkkat:	https://doi.org/10.1007/s13555-024-01174-4
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!